Logo image of BTCY

BIOTRICITY INC (BTCY) Stock Fundamental Analysis

NASDAQ:BTCY - Nasdaq - US09074H2031 - Common Stock - Currency: USD

0.4631  -0.18 (-28.31%)

After market: 0.431 -0.03 (-6.93%)

Fundamental Rating

1

Overall BTCY gets a fundamental rating of 1 out of 10. We evaluated BTCY against 39 industry peers in the Health Care Technology industry. BTCY has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, BTCY is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BTCY had negative earnings in the past year.
BTCY had a negative operating cash flow in the past year.
In the past 5 years BTCY always reported negative net income.
In the past 5 years BTCY always reported negative operating cash flow.
BTCY Yearly Net Income VS EBIT VS OCF VS FCFBTCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -251.17%, BTCY is not doing good in the industry: 94.74% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -251.17%
ROE N/A
ROIC N/A
ROA(3y)-244.13%
ROA(5y)-333.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTCY Yearly ROA, ROE, ROICBTCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

The Gross Margin of BTCY (69.32%) is better than 65.79% of its industry peers.
BTCY's Gross Margin has improved in the last couple of years.
BTCY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.62%
GM growth 5Y13.06%
BTCY Yearly Profit, Operating, Gross MarginsBTCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

0

2. Health

2.1 Basic Checks

BTCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
BTCY has more shares outstanding than it did 1 year ago.
BTCY has less shares outstanding than it did 5 years ago.
BTCY has a worse debt/assets ratio than last year.
BTCY Yearly Shares OutstandingBTCY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
BTCY Yearly Total Debt VS Total AssetsBTCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -34.76, we must say that BTCY is in the distress zone and has some risk of bankruptcy.
BTCY's Altman-Z score of -34.76 is on the low side compared to the rest of the industry. BTCY is outperformed by 94.74% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -34.76
ROIC/WACCN/A
WACC10.46%
BTCY Yearly LT Debt VS Equity VS FCFBTCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 0.20 indicates that BTCY may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.20, BTCY is doing worse than 92.11% of the companies in the same industry.
A Quick Ratio of 0.11 indicates that BTCY may have some problems paying its short term obligations.
The Quick ratio of BTCY (0.11) is worse than 94.74% of its industry peers.
Industry RankSector Rank
Current Ratio 0.2
Quick Ratio 0.11
BTCY Yearly Current Assets VS Current LiabilitesBTCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.07% over the past year.
Looking at the last year, BTCY shows a very strong growth in Revenue. The Revenue has grown by 25.12%.
The Revenue has been growing by 97.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)26.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.15%
Revenue 1Y (TTM)25.12%
Revenue growth 3Y52.82%
Revenue growth 5Y97.64%
Sales Q2Q%15.9%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y73.56%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year19.17%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BTCY Yearly Revenue VS EstimatesBTCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M
BTCY Yearly EPS VS EstimatesBTCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BTCY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BTCY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTCY Price Earnings VS Forward Price EarningsBTCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTCY Per share dataBTCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BTCY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOTRICITY INC

NASDAQ:BTCY (8/2/2024, 8:00:02 PM)

After market: 0.431 -0.03 (-6.93%)

0.4631

-0.18 (-28.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)06-27 2024-06-27/bmo
Earnings (Next)08-12 2024-08-12/amc
Inst Owners0.27%
Inst Owner Change-99.42%
Ins Owners25.75%
Ins Owner Change0%
Market Cap9.95M
Analysts43.33
Price Target4.08 (781.02%)
Short Float %1.04%
Short Ratio1.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP-0.12%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.63%
Min EPS beat(2)-27.72%
Max EPS beat(2)24.47%
EPS beat(4)2
Avg EPS beat(4)-7.11%
Min EPS beat(4)-27.72%
Max EPS beat(4)24.47%
EPS beat(8)5
Avg EPS beat(8)-4.43%
EPS beat(12)8
Avg EPS beat(12)-3.34%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.74%
Min Revenue beat(2)-2.84%
Max Revenue beat(2)-2.63%
Revenue beat(4)0
Avg Revenue beat(4)-6.02%
Min Revenue beat(4)-14.1%
Max Revenue beat(4)-2.63%
Revenue beat(8)2
Avg Revenue beat(8)-4.5%
Revenue beat(12)4
Avg Revenue beat(12)-3.5%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.82
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.66
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0.56
BVpS-1.4
TBVpS-1.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -251.17%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.32%
FCFM N/A
ROA(3y)-244.13%
ROA(5y)-333.78%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y22.62%
GM growth 5Y13.06%
F-Score5
Asset Turnover2.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.2
Quick Ratio 0.11
Altman-Z -34.76
F-Score5
WACC10.46%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.15%
EPS Next Y73.56%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)25.12%
Revenue growth 3Y52.82%
Revenue growth 5Y97.64%
Sales Q2Q%15.9%
Revenue Next Year19.17%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.6%
OCF growth 3YN/A
OCF growth 5YN/A